Formycon AG (FRA:FYB) OCF Margin %: 11.23% (As of Dec. 2025)


FRA:FYB Formycon AG FRA:FYB
64 GF Score
Price €18.56
GF Value €35.55
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Formycon AG OCF Margin %?

Formycon AG FRA:FYB -3.43% 64 OCF Margin % is 11.23% as of Dec. 2025. GuruFocus rates FRA:FYB with a GF Score™ of 64/100 and a GF Value™ of €35.55 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 958 Biotechnology companies, Formycon AG ranks better than 86.53% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Formycon AG's Cash Flow from Operations for the six months ended in Dec. 2025 was €3.99 Mil. Formycon AG's Revenue for the six months ended in Dec. 2025 was €35.48 Mil. Therefore, Formycon AG's OCF Margin % for the quarter that ended in Dec. 2025 was 11.23%.

As of today, Formycon AG's current OCF Yield % is 3.23%.

The historical rank and industry rank for Formycon AG's OCF Margin % or its related term are showing as below:

FRA:FYB' s OCF Margin % Range Over the Past 10 Years
Min: -44.42   Med: -14.63   Max: 30.93
Current: 24.24

During the past 13 years, the highest OCF Margin % of Formycon AG was 30.93%. The lowest was -44.42%. And the median was -14.63%.

FRA:FYB's OCF Margin % is ranked better than
86.53% of 958 companies
in the Biotechnology industry
Industry Median: -68.59 vs FRA:FYB: 24.24

Formycon AG OCF Margin % Related Terms

Formycon AG OCF Margin % Historical Data

* Premium members only.

The historical data trend for Formycon AG's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Formycon AG OCF Margin % Chart

Formycon AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -36.47 -44.42 -12.68 -33.33 24.24

Formycon AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.47 -115.96 18.62 75.56 11.23

FRA:FYB vs VRTX, REGN, ALNY: OCF Margin % Comparison

For the Biotechnology subindustry, Formycon AG's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Formycon AG OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Formycon AG's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Formycon AG's OCF Margin % falls into.


FRA:FYB
64GF Score
Formycon AG FRA:FYB
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Formycon AG OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Formycon AG's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=10.783/44.476
=24.24 %

Formycon AG's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=3.985/35.479
=11.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 11.23% mean?
Formycon AG (FRA:FYB) has a OCF Margin % of 11.23% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Formycon AG and its competitors. According to the industry distribution chart, Formycon AG ranks #129 out of 958 companies in the Biotechnology industry, placing it in the top 13.5%.
Is Formycon AG's OCF Margin % too high?
Formycon AG's current OCF Margin % is 11.23%. Based on the distribution chart, Formycon AG ranks #129 out of 958 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Formycon AG has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Formycon AG's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Formycon AG ranks #129 out of 958 companies for OCF Margin %. This places Formycon AG in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Formycon AG and its competitors. Formycon AG's current OCF Margin % is 11.23%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Formycon AG stock overvalued right now?
Based on GuruFocus' analysis, Formycon AG (FRA:FYB) is currently considered Possible Value Trap. The stock's GF Value™ is €35.55, compared to a current price of €18.56 — trading 47.8% below its estimated fair value. The current OCF Margin % is 11.23%. Formycon AG's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Formycon AG (FRA:FYB), the current OCF Margin % is 11.23% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Formycon AG (FRA:FYB) Overvalued in 2026?

Based on GuruFocus' analysis, Formycon AG stock appears to be undervalued. The current stock price of €18.56 is trading 47.8% below its estimated GF Value™ of €35.55. GuruFocus considers Formycon AG to be Possible Value Trap.

Key valuation signals for FRA:FYB:

  • OCF Margin %: 11.23%
  • GF Value™: €35.55 vs. price of €18.56 (47.8% below fair value)
  • GF Score™: 64/100 with 5 warning signs

No single metric tells the full story. See the FRA:FYB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Formycon AG Business Description

Address Fraunhoferstrasse 15, Martinsried, Planegg, BY, DEU, 82152
Formycon AG is an independent developer of high-quality biosimilars, which are follow-on products to biopharmaceutical drugs. The Company focuses on expanding and further developing its scalable biosimilar platform, which includes approved and pipeline products across ophthalmology, immunology, and immuno-oncology. Its key products include FYB201 (ranibizumab), FYB202 (ustekinumab), FYB203 (aflibercept), FYB206 (pembrolizumab), and FYB208 (dupilumab), along with additional biosimilar candidates in various stages of development. The Company generates maximum revenue from Switzerland.
64GF Score

Get the complete analysis for FRA:FYB

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€18.56
Price
€35.55
GF Value